Moreover, because GPER can be activated by tamoxifen, a drug that has been widely used to treat breast cancer for the last two decades, our work offers the possibility of repurposing tamoxifen to mechanically reprogram pancreatic and prostate cancer cells. This evidence concerns the gene GPER1 and prostate carcinoma.